Total Payments
$930,952
2024 Payments
$49,173
Companies
83
Transactions
1,507
Medicare Patients
9,394
Medicare Billing
$5.7M
Payment Breakdown by Category
Other$820,154 (88.1%)
Consulting$64,589 (6.9%)
Food & Beverage$27,549 (3.0%)
Travel$17,587 (1.9%)
Education$821.49 (0.1%)
Research$251.24 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $817,504 | 319 | 87.8% |
| Consulting Fee | $64,589 | 61 | 6.9% |
| Food and Beverage | $27,549 | 814 | 3.0% |
| Travel and Lodging | $17,587 | 266 | 1.9% |
| Honoraria | $1,900 | 2 | 0.2% |
| Education | $821.49 | 42 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $750.00 | 1 | 0.1% |
| Unspecified | $251.24 | 2 | 0.0% |
Payments by Type
General
$930,701
1,505 transactions
Research
$251.24
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $330,292 | 309 | $0 (2024) |
| Lilly USA, LLC | $159,815 | 199 | $0 (2024) |
| Merck Sharp & Dohme LLC | $66,788 | 64 | $0 (2024) |
| ABBVIE INC. | $61,612 | 68 | $0 (2024) |
| Amgen Inc. | $57,622 | 104 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $46,222 | 51 | $0 (2024) |
| Exelixis Inc. | $41,182 | 60 | $0 (2024) |
| Eisai Inc. | $38,766 | 52 | $0 (2024) |
| Janssen Biotech, Inc. | $33,300 | 78 | $0 (2024) |
| TAIHO ONCOLOGY, INC. | $28,364 | 34 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $49,173 | 116 | E.R. Squibb & Sons, L.L.C. ($19,836) |
| 2023 | $109,130 | 153 | E.R. Squibb & Sons, L.L.C. ($60,613) |
| 2022 | $114,495 | 192 | E.R. Squibb & Sons, L.L.C. ($57,349) |
| 2021 | $101,933 | 169 | E.R. Squibb & Sons, L.L.C. ($61,850) |
| 2020 | $54,042 | 113 | E.R. Squibb & Sons, L.L.C. ($24,067) |
| 2019 | $194,278 | 291 | Lilly USA, LLC ($37,455) |
| 2018 | $166,252 | 262 | Lilly USA, LLC ($37,575) |
| 2017 | $141,649 | 211 | Merck Sharp & Dohme Corporation ($48,092) |
All Payment Transactions
1,507 individual payment records from CMS Open Payments — Page 1 of 61
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,350.00 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $67.00 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $8.00 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $33.04 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Immunology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,717.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Genentech USA, Inc. | Lunsumio (Biological), Polivy | Food and Beverage | In-kind items and services | $34.69 | General |
| Category: BioOncology | ||||||
| 12/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.19 | General |
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $5.19 | General |
| Category: Cardiovascular | ||||||
| 11/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,350.00 | General |
| Category: Oncology | ||||||
| 11/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $33.50 | General |
| Category: Oncology | ||||||
| 11/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $8.00 | General |
| Category: Oncology | ||||||
| 11/24/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $112.40 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $25.12 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $122.79 | General |
| Category: Oncology | ||||||
| 11/18/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $31.09 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $121.89 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.34 | General |
| Category: Hematology | ||||||
| 11/04/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $23.31 | General |
| Category: Oncology | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $34.39 | General |
| Category: Oncology | ||||||
| 10/25/2024 | PFIZER INC. | XTANDI (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $9.09 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A phase 1b, open-label, dose-escalation study of the safety and pharmacology of GDC-0068 in combination with docetaxel, fluoropyrimidine plus oxaliplatin, paclitaxel, or enzalutamide in patients with advanced solid tumors | F. Hoffmann-La Roche AG | $236.62 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 46 | 2,240 | 86,974 | $4.8M | $1.2M |
| 2022 | 51 | 2,626 | 111,842 | $6.3M | $1.7M |
| 2021 | 43 | 2,270 | 49,341 | $3.8M | $1.1M |
| 2020 | 47 | 2,258 | 69,081 | $5.9M | $1.7M |
Total Patients
9,394
Total Services
317,238
Medicare Billing
$5.7M
Procedure Codes
187
All Medicare Procedures & Services
187 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 10,625 | $1.2M | $457,320 | 37.8% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 13 | 6,309 | $399,361 | $147,385 | 36.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 46 | 6,946 | $376,377 | $122,363 | 32.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 395 | 778 | $204,614 | $84,395 | 41.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 105 | 599 | $298,901 | $81,673 | 27.3% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 46 | 710 | $502,945 | $51,935 | 10.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 189 | 319 | $112,288 | $49,751 | 44.3% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 38 | 10,379 | $160,036 | $23,570 | 14.7% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 13 | 874 | $181,050 | $19,303 | 10.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 46 | 235 | $56,400 | $15,860 | 28.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 45 | 171 | $103,444 | $11,751 | 11.4% |
| 96416 | Administration of prolonged chemotherapy into vein | Office | 2023 | 15 | 70 | $29,680 | $9,554 | 32.2% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 22 | 24,990 | $274,890 | $9,448 | 3.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 93 | 110 | $38,720 | $9,429 | 24.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 42 | 42 | $20,916 | $8,099 | 38.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 200 | 949 | $24,674 | $7,222 | 29.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 45 | 45 | $18,000 | $6,510 | 36.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 58 | 222 | $25,308 | $6,510 | 25.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 106 | 486 | $26,730 | $6,385 | 23.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 36 | 204 | $22,440 | $5,848 | 26.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 58 | 75 | $13,050 | $5,539 | 42.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 76 | 343 | $25,725 | $5,365 | 20.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 71 | $10,508 | $4,981 | 47.4% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 50 | 137 | $19,180 | $4,518 | 23.6% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 17 | 77 | $15,631 | $4,386 | 28.1% |
About Dr. Ari Baron, M.D
Dr. Ari Baron, M.D is a Specialist healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013086420.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ari Baron, M.D has received a total of $930,952 in payments from pharmaceutical and medical device companies, with $49,173 received in 2024. These payments were reported across 1,507 transactions from 83 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($817,504).
As a Medicare-enrolled provider, Baron has provided services to 9,394 Medicare beneficiaries, totaling 317,238 services with total Medicare billing of $5.7M. Data is available for 4 years (2020–2023), covering 187 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location San Francisco, CA
- Active Since 11/07/2006
- Last Updated 07/08/2007
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1013086420
Products in Payments
- OPDIVO (Biological) $286,805
- VERZENIO (Drug) $67,156
- KEYTRUDA (Biological) $66,768
- RETEVMO (Drug) $47,360
- XGEVA (Biological) $46,381
- Nubeqa (Drug) $44,275
- CYRAMZA (Drug) $42,544
- Cabometyx (Drug) $38,876
- Lenvima (Drug) $38,714
- Venclexta (Drug) $31,100
- VENCLEXTA (Drug) $30,323
- Lonsurf (Drug) $28,324
- Erleada (Drug) $26,298
- ERLEADA (Drug) $16,778
- XTANDI (Drug) $16,253
- ELIQUIS (Drug) $14,607
- EMPLICITI (Biological) $9,619
- Avastin (Biological) $9,130
- Prolia (Biological) $6,756
- Neulasta (Biological) $4,162
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in San Francisco
Dr. Jeffrey Wolf, M.d, M.D
Specialist — Payments: $458,581
Specialist $458,581
Dr. Marc Simon, Md, MD
Specialist — Payments: $151,206
Specialist $151,206
Dr. Bruce Mccormack, Md, MD
Specialist — Payments: $140,445
Specialist $140,445
Dr. Christopher Pilcher, M.d, M.D
Specialist — Payments: $110,726
Specialist $110,726
Dr. Bertrand Tuan, M.d, M.D
Specialist — Payments: $96,251
Specialist $96,251
Kenneth Light, M.d, M.D
Specialist — Payments: $88,269
Specialist $88,269